Amol Pharmaceuticals Private Ltd. – FDA 483, Feb 16, 2018
The FDA inspection of Amol Pharmaceuticals Private Ltd. in Sanganer, India, revealed severe deficiencies across its quality control, production, and facility systems. Key issues included unreliable raw data, inadequate investigations into stability excursions and unknown contaminants, and unvalidated analytical methods and electronic systems. The firm also demonstrated poor documentation practices, incomplete equipment cleaning validation, unrecorded procedural deviations, and a lack of adequately trained personnel, indicating a systemic failure to ensure the quality and purity of drug products.
ID · 0b5934a4-2c98-44ea-ba0b-82991d8b73b0
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.